The Phase II trial NCT02936689 is studying DMF outcomes with ALS patients mainly using the biomarkers of oxidative stress, F2-isoprostanes, 8-OHdG, and oxidized SOD1. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.